Breaking News, Collaborations & Alliances

R&D Alliance for Eye Disease Cell Therapies

BlueRock Therapeutics, Fujifilm Cellular Dynamics, and Opsis Therapeutics enter R&D pact to discover and develop cell therapies for eye diseases.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

BlueRock Therapeutics, a clinical stage biopharmaceutical company and wholly-owned subsidiary of Bayer AG, Fujifilm Cellular Dynamics, a global developer and manufacturer of human induced pluripotent stem (iPS) cell technologies, and Opsis Therapeutics, a joint venture of Fujifilm Cellular Dynamics (FCDI) and David Gamm, focusing on developing cell therapies for patients with ocular diseases, have entered into a strategic research and development (R&D) alliance.   As part of the alliance, th...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters